Both CRP and PTX3 are expressed and upregulated under inflammatory conditions and may deposit locally at the site of tissue damage, also in complement-related diseases such as age-related macular degeneration and atypical hemolytic uremic syndrome (68–72). Here, PTX3 is linked to atypical hemolytic-uremic syndrome.